Crizotinib was approved by the Food and Drug Administration (FDA) of the United States in year 2011 for treatment of NSCLC patients, and with a companion diagnostic test, the Vysis ALK Break Apart FISH Probe Kit, that could help determine if a patient has the abnormal ALK gene [32]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.